Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24671964 | 0.88 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3KMT2AATM | |
| SCHEMBL16270678 | 0.88 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3KMT2AATM | |
| SCHEMBL19633928 | 0.88 | KMT2A (0.39) | SLC6A2SLC6A4SLC6A3KMT2AATM | |
| SCHEMBL270836 | 0.84 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3KMT2AATM | |
| SCHEMBL5865581 | 0.80 | KMT2A (0.47) | SLC6A2SLC6A4SLC6A3KMT2AATM | |
| SCHEMBL14322127 | 0.75 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3KMT2AATM | |
| SCHEMBL17904266 | 0.73 | CHRNB2 (0.39) | SLC6A2SLC6A4SLC6A3KMT2AATM | |
| SCHEMBL14282583 | 0.72 | MLKL (0.40) | KMT2A | |
| SCHEMBL10526789 | 0.72 | CHRNB2 (0.42) | SLC6A2SLC6A4SLC6A3KMT2AATM | |
| SCHEMBL19622556 | 0.69 | ESR1 (0.38) | SLC6A2SLC6A3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612538-B1 | QUINONE-METHIDE PRECURSORS WITH BODIPY CHROMOPHORE, METHOD OF PREPARATION, BIOLOGICAL ACTIVITY AND APPLICATION IN FLUORESCENT LABELLING | RUDJER BOSKOVIC INST (HR) | 2021-01-13 | — | — | EP | disclosed |
| US-20200197423-A1 | Quinone-methide precursors with bodipy chromophore, method of preparation, biological activity and application in fluorescent labelling | RUDJER BOSKOVIC INSTITUTE (HR) | 2020-06-25 | — | — | US | disclosed |
| WO-2017199056-A1 | QUINONE-METHIDE PRECURSORS WITH BODIPY CHROMOPHORE, METHOD OF PREPARATION, BIOLOGICAL ACTIVITY AND APPLICATION IN FLUORESCENT LABELLING | RUDJER BOSKOVIC INSTITUTE (HR) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197423-A1 | Quinone-methide precursors with bodipy chromophore, method of preparation, biological activity and application in fluorescent labelling | NQO2, NQO1, CYBA | SLC6A2 3225/4885SLC6A4 4352/4885SLC6A3 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.